Wegovy tablets: A complete guide to the new oral GLP-1

GLP-1s have changed the way the world thinks about weight management. For many women, though, the idea of a weekly injection has been a barrier between them and starting treatment. The new Wegovy tablet changes that.

The first oral GLP-1 pill for weight loss has been approved in the US by the FDA, meaning there is an opportunity to bring effective treatment to people who could not, or would not, use an injection.

Here is everything you need to know.

What are Wegovy tablets and why do they matter?

The new Wegovy tablet contains semaglutide. It is the first oral GLP-1 receptor agonist approved in the US by the FDA to specifically treat obesity. Made by Novo Nordisk, the Wegovy tablet offers a once-daily alternative to the weekly injection. And the good news? Both show comparable results in trials [1].

In June 2021, the FDA approved Wegovy injections in the US for weight management [5]. In September 2023, it was launched in the UK and became available on the NHS for specialist weight management services in line with NICE guidelines. Since then, it has been approved in multiple countries and has been prescribed to millions.

The pill version opens the door for adults with obesity who want the benefits of the treatment but feel more comfortable with an oral medication rather than an injection. For many women, the difference matters. Injections can sometimes feel intimidating, medical or simply unrealistic. A tablet can feel more familiar and discreet.

How do Wegovy tablets work in the body?

GLP-1 (glucagon-like peptide-1) is a natural hormone that your body releases after eating [6]. It signals fullness to the brain, slows the rate at which the stomach empties, and helps regulate blood sugar after a meal.

Semaglutide, the active ingredient in both Wegovy tablets and the Wegovy injection, is a GLP-1 receptor agonist. It mimics the natural hormone and activates the same receptors in your brain and gut [7]. Together, these effects can support weight loss by:

• Reducing hunger and food cravings
• Increasing feelings of fullness after smaller portions
• Slowing gastric emptying, so food stays in your stomach for longer
• Improving blood sugar control after meals by increasing insulin secretion

Although the oral form delivers semaglutide differently, the way it works is the same. The only difference is how the medication enters your bloodstream.

The challenge with an oral formulation is that semaglutide is a larger peptide molecule, which would typically be broken down by stomach acid before it reaches the bloodstream. Wegovy tablets use SNAC (salcaprozate sodium) technology, an absorption enhancer that temporarily protects the semaglutide from stomach acid and helps it pass through the stomach lining [1].

Wegovy tablets vs Wegovy injections

Both the pill version and injection contain semaglutide and achieve similar results when used as prescribed [2]. The differences are practical rather than clinical.

‍

You can switch between the tablet and injection, but it will need to be guided by a clinician. The doses are not directly interchangeable because of different dosing schedules and the way the medicine builds up in the body. A healthcare provider can carefully plan any switch to avoid gaps or overlaps.

Who are the new Wegovy tablets for?

Currently, in the US, the Wegovy tablets are approved for adults living with obesity (BMI of 30 or above) or overweight (BMI of 27 or above) with at least one weight-related health condition, such as high blood pressure, high cholesterol, obstructive sleep apnoea, or heart disease [3].

Once the Medicines and Healthcare products Regulatory Agency (MHRA) grants regulatory approval, prescribing criteria in the UK may differ from US guidance. NHS access may be more restricted based on NICE recommendations.

Juniper currently supports eligible women in the UK with GLP-1 injections plus health coaching, and similar medical screening would apply when the tablets become available.

Who should not take Wegovy tablets:

• Anyone with a personal or family history of medullary thyroid carcinoma
• People with Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Pregnant or breastfeeding women
• Those with severe stomach problems like gastroparesis
• Anyone with a history of pancreatitis

How to take Wegovy tablets (dosing and daily routine)

Like the injections, the Wegovy pill follows a gradual dose titration. This helps to minimise side effects and gives your body time to adjust. The typical treatment plan is [1]:

Days 1-30: 1.5mg once daily

Days 31-60: 4mg once daily

Days 61-90: 9mg once daily

Days 91 onwards: 25mg once daily

Each tablet should be taken first thing in the morning on an empty stomach. Swallow it whole with no more than 120 ml of plain water (not tea, coffee, or juice).

For best absorption [1]:

• Wait at least 30 minutes before eating food
• Don’t drink anything else during this 30-minute window
• Don’t take other medications for 30 minutes after taking Wegovy
• Don’t crush, chew, dissolve or split the semaglutide tablet

If you miss a dose, skip it and take your next dose at the usual time the following day. Do not take two tablets at once to make up for a missed dose.

Although this medication requires a consistent daily routine, many people find it manageable once it becomes part of their morning habits.

How effective are Wegovy tablets for weight loss?

Most of the evidence for the Wegovy pill comes from the OASIS 4 trial, a 71‑week, double‑blind, randomised, placebo‑controlled trial involving 205 participants with a BMI of 30 or over, without diabetes [3].

Key weight loss results [3]:

• Participants taking oral semaglutide lost about 16.6% of their starting body weight at 64 weeks (with full adherence)
• The placebo group lost only about 2.2%
• 28% of people lost 20% or more of their starting weight
• All participants followed a reduced‑calorie diet and increased physical activity

For comparison, once‑weekly Wegovy 2.4 mg injections show about 16.9% mean weight loss in similar trials, suggesting that average weight loss is broadly comparable between the tablet and injection [4].

However, individual results vary. Your experience will depend on:

• Your starting body weight and BMI
• Whether you reach higher doses without intolerable side effects
• How consistently you take the medication and follow lifestyle changes
• Diet quality and physical activity levels
• Genetic factors that influence metabolic health

It is important to remember that clinical trials take place in structured, highly supported environments. Real‑world results may differ, and there are no guaranteed outcomes.

Side effects and safety of Wegovy tablets

Because Wegovy tablets and injections share the same active ingredient, their safety profiles are very similar. Most of the side effects affect the digestive system and are most noticeable when the dose is increasing.

Common side effects include [1]:

• Nausea
• Diarrhoea
• Vomiting
• Constipation
• Stomach pain and upset stomach
• Indigestion and bloating
• Runny nose and sore throat

More serious but less common risks [1]:

• Pancreatitis — seek medical help immediately if you experience severe stomach pain
• Gallbladder problems
• Kidney problems (often linked to dehydration from vomiting or diarrhoea)
• Low blood sugar, especially if combined with insulin or sulfonylureas (know how to treat low blood sugar)
• Serious allergic reaction (rare)
• Vision changes in those with type 2 diabetes
• Increase heart rate
• Stomach problems

Wegovy carries a boxed warning about a potential risk of thyroid C‑cell tumours based on animal studies. It is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or MEN2. While the risk to humans is not confirmed, it requires careful discussion with a clinician [1].

Drug interactions

Because Wegovy slows gastric emptying, it can affect how your body absorbs other oral medications, including some contraceptive pills and HRT. Your prescriber may adjust timings or recommend backup contraception.

This information does not replace individual medical advice. You should always discuss the risks and benefits with your GP or an obesity specialist before starting any weight loss injections or tablets.

Cost, access, and availability

As of April 2026, Wegovy tablets are only FDA‑approved and commercially available in the US. Regulatory submissions are in progress elsewhere, but decisions have not yet been made.

If you are in the UK, it is important not to buy “Wegovy pills” from unregulated online sources. These products may be counterfeit, incorrectly dosed, or supplied without proper medical supervision. This can carry serious risks.

You may also have heard of oral semaglutide for diabetes, sold as Rybelsus. Rybelsus is available in the UK but is licensed for type 2 diabetes at a lower dose, not for weight loss. Any off‑label use should only ever happen under specialist medical guidance. It is not safe to take someone else’s diabetes medication or to buy it online for weight loss.

When will Juniper offer the Wegovy tablet?

Juniper provides a holistic, long-term approach to weight management for women who want to lose weight sustainably, and we are closely following the arrival of Wegovy tablets in the UK.

While the tablet is not yet approved here, that is expected to change. When it does, Juniper will be ready. In the meantime, our programme already provides eligible women with access to GLP-1 medications, health coaching, and ongoing clinical support, so you don't have to wait to get started.

If you want to find out more about how GLP-1 treatment could help you manage your weight, you can complete an online assessment to check your eligibility.

Frequently asked questions

Can I switch from the Wegovy injection to Wegovy tablets?

It is possible to switch, but it needs to be managed by a clinician. Although both medications contain semaglutide, the doses are not directly equivalent as one form is taken daily and the other weekly. If you are interested in the oral form, speak to your prescriber. Do not stop or switch your current prescription without medical supervision.

Can I use Rybelsus instead of Wegovy tablets for weight loss?

Rybelsus is an oral semaglutide tablet that is approved for type 2 diabetes, not specifically for weight loss. It uses a lower maximum dose than the Wegovy pill. Some clinicians may consider off‑label use in particular cases, but this is not routine and should never be self‑directed. Do not take someone else’s Rybelsus or buy it online for weight loss purposes without proper medical guidance.

What happens if I can’t stick to the 30-minute fasting window?

Eating food or drinking other liquids too soon after taking the tablet reduces absorption, which may make the medicine less effective. If you find the 30‑minute window difficult to manage regularly, speak to your prescriber. They may suggest practical strategies to build the routine into your morning, or they may recommend switching to the weekly injection instead. Occasional timing slips are common and do not mean you should stop treatment immediately. However, consistency over time does matter for the best results.

Will I gain weight back if I stop taking Wegovy tablets?

Data from injectable semaglutide show that many people regain at least some weight after stopping treatment, because the medication is no longer helping to reduce appetite. Long‑term habits built during treatment can make a real difference to how much weight is regained. Obesity is usually a chronic health condition that requires ongoing management. If you are thinking about pausing or stopping treatment, discuss this with your doctor first. You may also want to consider continued support through programmes such as Juniper to help you maintain your progress over the long term.

Image credit: Pexels